Skip to main content

Blood Cancers

a uva health doctor meets with a blood cancer patient

Getting a leukemia, lymphoma, or bone marrow cancer diagnosis can be frightening. Your body feels weak and sick. It's hard to know where to go for the best blood cancer treatment.

Treating blood cancer takes experience, expertise, compassion, and collaboration. You'll find all of this and more at UVA Health.

Our leukemia, lymphoma, and myeloma care is recognized as some of the best in the country. U.S. News & World Report rated our care as "high-performing," their highest rating.
Our leukemia, lymphoma, and myeloma care is recognized as some of the best in the country. U.S. News & World Report rated our care as "high-performing," their highest rating.

Why UVA Health for Blood Cancer Treatment

UVA Health is Virginia's first National Cancer Institute Comprehensive Cancer Center. This title honors our leadership in cancer research, diagnosis, treatment, and prevention. 

You can rely on UVA Health to use highly advanced tools. You'll get the right diagnoses as soon as possible. And we bring you the newest life-saving therapies through clinical trials.

Learn more about why you should choose a Comprehensive Cancer Center.

Blood Cancer Treatment Expertise

UVA Health helped develop some of the latest blood cancer treatments. These include therapies that target cancer without hurting healthy cells.

You'll get access to innovations that include:

As an academic research center, our highly-trained providers work with diligent researchers to offer personalized treatment plans.

Experts Who Care

We're invested in helping every patient we see recover and thrive.

Our people offer:

  • Deep experience
  • A team-based approach
  • Specialists in every major form of blood cancer
  • Compassionate, welcoming support services
  • A calming, healing environment without the added stress of a city

We also:

Team Expertise

We have decades of experience in blood cancer. We're dedicated to your care.

Get a Second Opinion for Your Blood Cancer

Which treatment will work for you depends on your condition and health. If it turns out you need treatment from another institution, we'll make sure you get it. It's about finding what's best for each patient.

Feel confident about your care. See how to get a second opinion.

Care Close to Home

For our patients in Northern Virginia, Prince William Medical Center offers a monthly hematology and oncology clinic. This allows you see our blood cancer and blood disorder experts closer to home.

A nurse caring for her patient

A Transplant for All Who Need It

We're working to end blood cancer's greater toll on the Black community by making sure everyone who needs a stem cell transplant can get one.

Read More

Blood Cancers We Treat

Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia (AML)

Chronic Lymphocytic Leukemia (CLL)

Chronic Myelogenous Leukemia

Non-Hodgkin & Hodgkin Lymphoma

LGL Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Waldenstrom Macroglobulinemia

Blood Cancer Treatments

Blood Cancer Treatment Clinical Trials
Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies, and Marrow Toxic Injuries

The University of Virginia Cancer Center seeks participants for a Research Database that collects data on the outcomes of stem cell transplants and other cellular treatments. The Research Database is a comprehensive source of data that can be used to study hematopoietic cell transplantation (HCT) and cellular therapy (CT). The sponsor of this study, the Center for International Blood and Marrow Transplant Research (CIBMTR) uses the data in order to find ways to make bone marrow and stem cell transplants work better for both recipients and donors. Medical data about your disease and your treatment will be reported to the CIBMTR. Participating in this Research Database will not cost you any money. Your insurance company will also not be billed. Additional information can be found here: https://clinicaltrials.gov/study/NCT04920474 [email protected] The (department, division name) seeks (insert as applies: adults/men/women/adolescents/children) ages (insert) with (insert condition) for a research study. The purpose of the study is (insert purpose of study - eg.to test the effectiveness of an investigational medicine; or to find out how stress effects blood pressure.) (Optional)You may be eligible for this study if: (insert brief eligibility criteria 3 or 4 top criteria and in lay language. Do not copy eligibility criteria from the protocol) Study involves (insert procedures-examples: taking an experimental medicine/placebo, blood draws, x rays, overnight stays,) (Insert x number of visits every x (weeks, months,) each visit lasting x amount of time or give range). Insert one of the following: Study-related (insert exams, tests and experimental medication) provided at no cost. or Participant’s insurance company will be billed for medication, tests and procedures

Blood Sample Banking For Future Research

The UVA Cancer Center seeks adults over the age of 18 to participate in a research study to store blood samples in a repository for future research. A repository is like a bank, where blood samples are frozen and stored. The exact research that will be done on the stored samples is not known at this time; however, researchers may use these samples to learn more about: • What affects transplant and cellular therapy results • The distribution of tissue type in populations • How to match donors and patients for bone marrow transplants If you agree to participate, you will be asked to provide about 2 tablespoons of blood before your transplant or cellular therapies. If you agree to participate and you are a donor, 2 tablespoons of blood will be collected before or shortly after your donation. In the future, we may ask you for another blood sample and at that time, you can choose to give another sample if you want to. Study-related (insert exams, tests and experimental medication) provided free of charge.

A phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-hodgkin lymphoma (NHL)

The University of Virginia Cancer Center seeks participants 18 years old or above to participate in a study that looks at a new treatment for follicular or marginal zone lymphoma that has not responded to or returned after previous treatments. The JCAR-017 treatment works on the T-cells in the body (part of the immune system). Participation on this study involves up to 26 weeks. Participants are also required to take part in a 15-year long-term follow up study. Study-related tests and procedures and study drug will be covered by the study sponsor. Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04245839

Study For Patients With Newly Diagnosed Acute Myeloid Leukemia To See If Drugs for Treating Heart Problems May Help To Prevent Heart Problems

The University of Virginia Cancer Center is conducting a clinical research study for patients with newly diagnosed acute myeloid leukemia (AML). One of the drugs used in the standard treatment for AML can increase risk of damage to the heart. Beta blockers and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used to treat people who have this kind of damage to the heart. These drugs are taken orally (pills taken by mouth). The purpose of this study is to see how often newly diagnosed AML patients that receive these drugs during initial treatment develop this type of damage and how often this damage develops in people who don’t receive these drugs preventively. Participants will be randomly assigned to receive the drugs preventively with their standard clinical treatment or to receive standard clinical treatment without these drugs (unless they are needed for treating heart damage). Participants will not get to choose which group they are assigned to, but they will know what they are receiving. The beta blockers and ACE inhibitors used in this study are approved by the FDA for treating heart damage but not approved to prevent heart damage in this population. Participants will receive study treatment for as long as they are receiving standard clinical care that includes a drug that increases risk of this heart damage and for about 3 months afterward. Before, during and after study treatment, participants will be asked to complete questionnaires about their quality of life. Before and during study treatment, participants will have frequent electrocardiograms (ECGs/EKGs) and blood tests to look at their heart function. Participants will be followed after they have completed the study treatment for about 6 months. Study-specific tests that are being done beyond standard of care will be provided at no cost to the patient/participant or his/her/their insurance. For more information, please visit Cardioprotection - clinicaltrials.gov or contact the study team at [email protected].

A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (AAML1831)

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been recently diagnosed with acute myeloid leukemia (AML). This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone. Additional information can be found here: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations - Full Text View - ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT04293562)

View All Clinical Trials

Related Locations

Find a Related Provider

Start Search